Reviewed October 30, 2026 · Research-use information
the short answer
There is no proven safety profile. TB-500 is a research peptide, not an FDA-approved veterinary drug, and no controlled canine trials have established a dose, benefit, or long-term safety. The FDA says it lacks important safety information and flags immunogenicity and impurity concerns. Preclinical data is not a canine safety study. Ask your vet, especially for dogs with cancer, pregnancy, or medication use.
| Question | Answer | Basis |
|---|---|---|
| FDA-approved for dogs? | No | Not an approved animal drug |
| Controlled canine trials? | None completed | No canine efficacy or safety data |
| Human TB-500 safety data? | FDA says none identified | Bulk-substance safety note |
| Long-term canine safety? | Unknown | No controlled canine data |
| Product quality? | Variable; FDA flags aggregation and impurities | Compounding safety note |
Status as of October 30, 2026. A research-use product, not an approved veterinary drug.
What TB-500 is
TB-500 is a synthetic seven-amino-acid fragment of thymosin beta-4, sometimes written as LKKTETQ. Thymosin beta-4 is a larger protein involved in cell migration and tissue repair. TB-500 is not the same molecule as full-length thymosin beta-4, and a 2026 orthopaedic review says the two are frequently conflated despite no validated biologic or clinical equivalence. That distinction matters when someone quotes a TB-4 study as if it were a TB-500 study.
What the evidence shows
The same 2026 review says thymosin beta-4 has broader experimental and human experience in ophthalmic, dermatologic, and cardiovascular applications, but direct musculoskeletal evidence remains limited to in-vitro and rodent studies. Direct musculoskeletal evidence for TB-500 specifically is also limited to in-vitro and rodent studies. No controlled canine trial has established a dose, a benefit, or long-term safety for the uses owners ask about. Preclinical plausibility is not a canine safety profile.
What the FDA says
The FDA's bulk-substance page says compounded drugs containing the thymosin beta-4 fragment known as TB-500 may pose a risk for immunogenicity for certain routes of administration due to the potential for aggregation, as well as peptide-related impurities. The agency says it has not identified any human exposure data for the fragment and lacks important safety information, including whether it would cause harm. That is regulatory caution, not a finding of safety.
Why 'research use' is not a safety review
A research-use label is a marketing statement, not an FDA approval. Animal drugs compounded from bulk substances are not FDA-approved and have not been reviewed for safety, effectiveness, manufacturing, or labeling. Compounders of those products are not required to report adverse events to FDA the way approved-drug sponsors are. A batch certificate of analysis is useful documentation, but it is not a safety study and it does not replace a veterinary exam.
Dogs who need extra caution
Be especially careful with puppies, pregnant or nursing dogs, dogs with active cancer, dogs on immunosuppressive medication, and dogs recovering from surgery. A dog with a serious illness or a complicated medication list should not be started on a research peptide without a vet's review. If your dog is suddenly lame, yelping, dragging a leg, or unable to bear weight, that is a vet call first, not a pen question.
If you and your vet proceed
Start with an exam and a diagnosis. Bring the product label, the batch certificate, and the full medication list. Confirm the weight band and the 28-day use window. Keep a daily log of appetite, energy, gait, and any reaction at the injection site. Stop and call your vet if something changes. A batch certificate is not a safety guarantee, but it is the minimum documentation for a research-use product.
What we do not claim
- We do not claim TB-500 is safe for every dog.
- We do not claim it is proven to work or to be risk-free.
- We do not claim it is FDA-approved or a substitute for vet care.
- We do not claim that the absence of reported harm equals safety.
Sources
Reviewed October 30, 2026. These are the sources we used for this page. Dollar figures, where present, are estimates from the named source, not quotes.
- FDA: Certain Bulk Drug Substances for Use in CompoundingTB-500 immunogenicity, aggregation, and impurity concerns; content current April 22, 2026.
- PubMed: Investigational peptides in orthopaedic practice (2026)TB-500 is a distinct TB-4 fragment; direct musculoskeletal evidence is limited to in-vitro and rodent studies.
- FDA: Animal Drug CompoundingBulk-compounded animal drugs are not FDA-approved and lack premarket review.
- AVMA: Your pet's medicationsTell your vet about every medication and supplement; do not give human medications without advice.
Questions owners ask
Is TB-500 FDA-approved for dogs?
No. It is not an FDA-approved veterinary drug, and no controlled canine trials have been completed for the uses owners ask about.
Has TB-500 been studied in dogs?
The musculoskeletal evidence is preclinical, including in-vitro and rodent work. Controlled canine trials are lacking.
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a seven-amino-acid fragment of thymosin beta-4. A 2026 review says the two are often conflated despite no validated biologic or clinical equivalence.
What should I ask my vet?
Ask about the diagnosis, interactions with current medications, the weight band, what to monitor, and what would make them stop. Bring the label and batch certificate.